Welcome to our dedicated page for JanOne news (Ticker: JAN), a resource for investors and traders seeking the latest updates and insights on JanOne stock.
JanOne Inc. (NASDAQ: JAN) combines groundbreaking biotech research with innovative fintech solutions, offering investors and industry observers a unique dual-sector perspective. This centralized news hub provides timely updates on the company's development of non-addictive pain therapies and blockchain-powered financial services through its ALT5 Sigma subsidiary.
Visitors will find comprehensive coverage of clinical trial progress, regulatory milestones, and strategic initiatives across both healthcare and digital finance sectors. Key updates include pharmaceutical pipeline developments, cryptocurrency payment platform enhancements, and corporate financial disclosures.
The curated news feed serves as a strategic resource for tracking JAN's progress in addressing opioid dependency through novel therapeutics while monitoring its expansion into blockchain-based financial infrastructure. Regular updates ensure stakeholders stay informed about cross-industry innovations from this multidisciplinary organization.
Bookmark this page for streamlined access to official press releases, earnings reports, and market analyses related to JanOne's pioneering work in pain management and digital asset solutions.
JanOne (NASDAQ: JAN) announced a successful pre-IND meeting with the FDA on April 18, 2023, regarding Jan123, a low dose naltrexone aimed at treating complex regional pain syndrome (CRPS). This rare disease causes severe pain and has no current cure. The FDA's feedback gives JanOne a pathway for submitting a New Drug Application under the 505(b)(2) designation. Key discussion points included preclinical toxicology and clinical implementation, which are crucial for progressing Jan123 towards formal approval. Both JanOne's Chief Medical Officer and CEO expressed optimism about the therapeutic potential of Jan123 and its role in addressing the opioid crisis. The company emphasizes its commitment to innovative pain management solutions.
JanOne (Nasdaq: JAN), represented by Dr. Amol Soin, will present at the Appalachian Region Spine and Pain Meeting on April 15, 2023, discussing innovation in pain medicine and the company’s drug development programs. JanOne focuses on non-opioid treatments for pain management, introducing two late-stage drug candidates: JAN 101, aimed at treating peripheral artery disease and diabetic neuropathy, and JAN 123, a low-dose naltrexone for Complex Regional Pain Syndrome, which received orphan drug status from the FDA. Dr. Soin aims to highlight the need for effective pain management solutions amid the opioid crisis, which underscores JanOne's commitment to developing non-addictive medication options. The meeting will serve as a platform to engage physicians seeking alternatives to opioids.
JanOne, a biopharmaceutical company on Nasdaq (JAN), announced the appointment of John N. Bonfiglio, PhD, as the interim president of its subsidiary, JanOne Biotech. His extensive background in leading successful biotech firms includes raising over
FAQ
What is the current stock price of JanOne (JAN)?
What is the market cap of JanOne (JAN)?
